The Role of Oxidative Stress in Breast Cancer

Cancer: Oxidative Stress and Dietary Antioxidants

Volumn , Issue , 2014, Pages 3-14

  Devi, Gayathri R ^a   Allensworth, Jennifer L ^a   Evans, Myron K ^a   Sauer, Scott J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aging; Antioxidants; Apoptosis; Epigenetics; Estrogen; Hypoxia; Inflammation; Reactive oxygen species; Redox adaptation; Superoxide dismutase

Indexed keywords

EID: 84902057898     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-405205-5.00001-5     Document Type: Chapter

References (81)

1. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002, 82(1):47-95.
2. Han D., Williams E., Cadenas E. Mitochondrial respiratory chain-dependent generation of superoxide anion and its release into the intermembrane space. Biochem J 2001, 353(Pt 2):411-416.
3. Winterbourn C.C. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 2008, 4(5):278-286.
4. Hirst D.G., Robson T. Nitrosative stress in cancer therapy. Front Biosci 2007, 12:3406-3418.
5. Nitta M., Kozono D., Kennedy R., Stommel J., Ng K., Zinn P.O., et al. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PloS one 2010, 5(5):e10767.
6. Ziech D., Franco R., Georgakilas A.G., Georgakila S., Malamou-Mitsi V., Schoneveld O., et al. The role of reactive oxygen species and oxidative stress in environmental carcinogenesis and biomarker development. Chem Biol Interact 2010, 188(2):334-339.
7. McCord J.M., Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969, 244(22):6049-6055.
8. Samoylenko A., Hossain J.A., Mennerich D., Kellokumpu S., Hiltunen J.K., Kietzmann T. Nutritional Countermeasures Targeting Reactive Oxygen Species in Cancer: From Mechanisms to Biomarkers and Clinical Evidence. Antioxid Redox Signal 2013.
9. Wells P.G., McCallum G.P., Chen C.S., Henderson J.T., Lee C.J., Perstin J., et al. Oxidative stress in developmental origins of disease: Teratogenesis, neurodevelopmental deficits, and cancer. Toxicol Soc 2009, 108(1):4-18.
10. Indran I.R., Hande M.P., Pervaiz S. hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells. Cancer Res 2011, 71(1):266-276.
11. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., et al. p53 regulates mitochondrial respiration. Science (New York, NY) 2006, 312(5780):1650-1653.
12. Yagoda N., von Rechenberg M., Zaganjor E., Bauer A.J., Yang W.S., Fridman D.J., et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 2007, 447(7146):864-868.
13. Ambrosone C.B. Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2000, 2(4):903-917.
14. Bartosz G. Reactive oxygen species: Destroyers or messengers?. Biochem Pharmacol 2009, 77(8):1303-1315. 10.016/j.bcp.2008.11.009. Epub Nov 24.
15. Forman H.J., Maiorino M., Ursini F. Signaling functions of reactive oxygen species. Biochemistry 2010, 49(5):835-842. 10.1021/bi9020378.
16. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach?. Nat Rev Drug Discov 2009, 8(7):579-591.
17. Zhao Y., Robbins D. Manganese superoxide dismutase in cancer prevention. Antioxid Redox Signal 2013.
18. Robinson M.F., Godfrey P.J., Thomson C.D., Rea H.M., van Rij A.M. Blood selenium and glutathione peroxidase activity in normal subjects and in surgical patients with and without cancer in New Zealand. Am J Clin Nutr 1979, 32(7):1477-1485.
19. Maitra A., Wistuba, Washington C., Virmani A.K., Ashfaq R., Milchgrub S., et al. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am J Pathol 2001, 159(1):119-130.
20. Esworthy R.S., Baker M.A., Chu F.F. Expression of selenium-dependent glutathione peroxidase in human breast tumor cell lines. Cancer Res 1995, 55(4):957-962.
21. Williams K.J., Cowen R.L., Stratford I.J. Hypoxia and oxidative stress. Tumour hypoxia-Therapeutic considerations. Breast Cancer Res 2001, 3(5):328-331.
22. Generali D., Berruti A., Brizzi M.P., Campo L., Bonardi S., Wigfield S., et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006, 12(15):4562-4568.
23. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999, 59(22):5830-5835.
24. Brown N.S., Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001, 3(5):323-327.
25. Wincewicz A., Koda M., Sulkowska M., Kanczuga-Koda L., Wincewicz D., Sulkowski S. STAT3 and hypoxia induced proteins-HIF-1alpha, EPO and EPOR in relation with Bax and Bcl-xL in nodal metastases of ductal breast cancers. Folia histochemica et cytobiologica / Polish Academy of Sciences. Folia Histochem Cytobiol 2009, 47(3):425-430.
26. Whelan K.A., Schwab L.P., Karakashev S.V., Franchetti L., Johannes G.J., Seagroves T.N., et al. The Oncogene HER2/neu (ERBB2) Requires the Hypoxia-inducible Factor HIF-1 for Mammary Tumor Growth and Anoikis Resistance. J Biol Chem 2013, 288(22):15865-15877.
27. Chen C.L., Chu J.S., Su W.C., Huang S.C., Lee W.Y. Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1alpha, GLUT1, and CAIX. Virchows Arch 2010, 457(1):53-61.
28. Blancher C., Moore J.W., Talks K.L., Houlbrook S., Harris A.L. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 2000, 60(24):7106-7113.
29. Lal A., Peters H., St Croix B., Haroon Z.A., Dewhirst M.W., Strausberg R.L., et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001, 93(17):1337-1343.
30. Lithgow D., Covington C. Chronic inflammation and breast pathology: A theoretical model. Biol Res Nurs 2005, 7(2):118-129.
31. Simpson E.R., Brown K.A. Minireview: Obesity and breast cancer: A tale of inflammation and dysregulated metabolism. Mol Endocrinol 2013, 27(5):715-725.
32. Ristimaki A., Sivula A., Lundin J., Lundin M., Salminen T., Haglund C., et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002, 62(3):632-635.
33. Khuder S.A., Mutgi A.B. Breast cancer and NSAID use: A meta-analysis. Br J Cancer 2001, 84(9):1188-1192.
34. Simpson E.R., Clyne C., Rubin G., Boon W.C., Robertson K., Britt K., et al. Aromatase-A brief overview. Annu Rev Physiol 2002, 64:93-127.
35. Clemons M., Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001, 344(4):276-285.
36. Sastre-Serra J., Valle A., Company M.M., Garau I., Oliver J., Roca P. Estrogen down-regulates uncoupling proteins and increases oxidative stress in breast cancer. Free Radic Biol Med 2010, 48(4):506-512.
37. Nadal-Serrano M., Sastre-Serra J., Pons D.G., Miro A.M., Oliver J., Roca P. The ERalpha/ERbeta ratio determines oxidative stress in breast cancer cell lines in response to 17beta-estradiol. J Cell Biochem 2012, 113(10):3178-3185.
38. Howlander N, Noone AM, Krapcho M, Garshell J, Neyman N, Altedruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, D.R. L, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2010. National Cancer Institute Bethesda, MD, based on November 2012 SEER data submission. (based on November 2012 SEER data submission, posted to the SEER web site, April 2013). http://seercancergov/csr/1975_2010/.
39. Mates J.M., Segura J.A., Alonso F.J., Marquez J. Intracellular redox status and oxidative stress: Implications for cell proliferation, apoptosis, and carcinogenesis. Arch Toxicol 2008, 82(5):273-299.
40. Hou Z., Falcone D.J., Subbaramaiah K., Dannenberg A.J. Macrophages induce COX-2 expression in breast cancer cells: Role of IL-1beta autoamplification. Carcinogenesis 2011, 32(5):695-702.
41. Donate L.E., Blasco M.A. Telomeres in cancer and ageing. Philosophical transactions of the Royal Society of London Series B. Biol Sci 2011, 366(1561):76-84.
42. Singhapol C., Pal D., Czapiewski R., Porika M., Nelson G., Saretzki G.C. Mitochondrial telomerase protects cancer cells from nuclear DNA damage and apoptosis. PloS one 2013, 8(1):e52989.
43. Aapro M., Wildiers H. Triple-negative breast cancer in the older population. Ann Oncol 2012, 23(Suppl. 6). vi52-5.
44. Cui H., Kong Y., Zhang H. Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct 2012, 2012:646354.
45. Rohan T.E., Wong L.J., Wang T., Haines J., Kabat G.C. Do alterations in mitochondrial DNA play a role in breast carcinogenesis?. J Oncol 2010, 2010:604304.
46. Ziech D., Franco R., Pappa A., Panayiotidis M.I. Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res 2011, 711(1-2):167-173.
47. Schafer F.Q., Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 2001, 30(11):1191-1212.
48. Jardim B.V., Moschetta M.G., Leonel C., Gelaleti G.B., Regiani V.R., Ferreira L.C., et al. Glutathione and glutathione peroxidase expression in breast cancer: An immunohistochemical and molecular study. Oncol Rep 2013.
49. Chen E.I., Hewel J., Krueger J.S., Tiraby C., Weber M.R., Kralli A., et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 2007, 67(4):1472-1486.
50. Singh B., Tai K., Madan S., Raythatha M.R., Cady A.M., Braunlin M., et al. Selection of metastatic breast cancer cells based on adaptability of their metabolic state. PLoS One 2012, 7(5):e36510. Epub 2012 May 3. 10.1371/journal.pone.0036510.
51. Bae I., Fan S., Meng Q., Rih J.K., Kim H.J., Kang H.J., et al. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 2004, 64(21):7893-7909.
52. Weydert C.J., Waugh T.A., Ritchie J.M., Iyer K.S., Smith J.L., Li L., et al. Overexpression of manganese or copper-zinc superoxide dismutase inhibits breast cancer growth. Free Radic Biol Med 2006, 41(2):226-237.
53. Kattan Z., Minig V., Leroy P., Dauca M., Becuwe P. Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells. Breast Cancer Res Treat 2008, 108(2):203-215.
54. Er T.K., Hou M.F., Tsa E.M., Lee J.N., Tsai L.Y. Differential expression of manganese containing superoxide dismutase in patients with breast cancer in Taiwan. Ann Clin Lab Sci 2004, 34(2):159-164.
55. Aird K.M., Allensworth J.L., Batinic-Haberle I., Lyerly H.K., Dewhirst M.W., Devi G.R. ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat 2012, 132(1):109-119.
56. Williams K.P., Allensworth J.L., Ingram S.M., Smith G.R., Aldrich A.J., Sexton J.Z., et al. Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization. Cancer Lett 2013, 17(13):386-388.
57. Allensworth J.L., Aird K.M., Aldrich A.J., Batinic-Haberle I., Devi G.R. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Mol Cancer Ther 2012, 11(7):1518-1527.
58. Tas F., Hansel H., Belce A., Ilvan S., Argon A., Camlica H., et al. Oxidative stress in breast cancer. Med Oncol 2005, 22(1):11-15.
59. Ray G., Batra S., Shukla N.K., Deo S., Raina V., Ashok S., et al. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Treat 2000, 59(2):163-170.
60. Portakal O., Ozkaya O., Erden Inal M., Bozan B., Kosan M., Sayek I. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 2000, 33(4):279-284.
61. Kumaraguruparan R., Subapriya R., Viswanathan P., Nagini S. Tissue lipid peroxidation and antioxidant status in patients with adenocarcinoma of the breast. Clin Chim Acta 2002, 325(1-2):165-170.
62. Punnonen K., Ahotupa M., Asaishi K., Hyoty M., Kudo R., Punnonen R. Antioxidant enzyme activities and oxidative stress in human breast cancer. J Cancer Res Clin Oncol 1994, 120(6):374-377.
63. Kumaraguruparan R., Kabalimoorthy J., Nagini S. Correlation of tissue lipid peroxidation and antioxidants with clinical stage and menopausal status in patients with adenocarcinoma of the breast. Clin Biochem 2005, 38(2):154-158.
64. Manda G., Nechifor M.T., Neagu T. Reactive Oxygen Species, Cancer and Anti-Cancer Therapies. Curr Chem Biol 2009, 3:342-366.
65. Noh D.Y., Ahn S.J., Lee R.A., Kim S.W., Park I.A., Chae H.Z. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 2001, 21(3B):2085-2090.
66. Balkwill F. Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev 2002, 13(2):135-141.
67. Tian H., Zhang B., Di J., Jiang G., Chen F., Li H., et al. Keap1: One stone kills three birds Nrf2, IKKbeta and Bcl-2/Bcl-xL. Cancer Lett. 2012, 325(1):26-34. Epub Jun 26. 10.1016/j.canlet.2012.06.007.
68. Bharti A.C., Aggarwal B.B. Nuclear factor-kappa B and cancer: Its role in prevention and therapy. Biochem Pharmacol 2002, 64(5-6):883-888.
69. Morgan M.J., Liu Z.G. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 2011, 21(1):103-115.
70. Yook J.I., Li X.Y., Ota I., Hu C., Kim H.S., Kim N.H., et al. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol 2006, 8(12):1398-1406.
71. Lu Z., Xu S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 2006, 58(11):621-631.
72. Truong T.H., Carroll K.S. Redox regulation of epidermal growth factor receptor signaling through cysteine oxidation. Biochemistry 2012, 51(50):9954-9965.
73. Badawi A.F., Cavalieri E.L., Rogan E.G. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism 2001, 50(9):1001-1003.
74. Bolton J.L., Thatcher G.R. Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol 2008, 21(1):93-101.
75. Tanaka T., Iwasa Y., Kondo S., Hiai H., Toyokuni S. High incidence of allelic loss on chromosome 5 and inactivation of p15INK4B and p16INK4A tumor suppressor genes in oxystress-induced renal cell carcinoma of rats. Oncogene 1999, 18(25):3793-3797.
76. Browne E.P., Punska E.C., Lenington S., Otis C.N., Anderton D.L., Arcaro K.F. Increased promoter methylation in exfoliated breast epithelial cells in women with a previous breast biopsy. Epigenetics 2011, 6(12):1425-1435.
77. Hitchler M.J., Wikainapakul K., Yu L., Powers K., Attatippaholkun W., Domann F.E. Epigenetic regulation of manganese superoxide dismutase expression in human breast cancer cells. Epigenetics 2006, 1(4):163-171.
78. Barbano R., Muscarella L.A., Pasculli B., Valori V.M., Fontana A., Coco M., et al. Aberrant Keap1 methylation in breast cancer and association with clinicopathological features. Epigenetics 2013, 8(1):105-112.
79. Eades G., Yang M., Yao Y., Zhang Y., Zhou Q. miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells. J Biol Chem 2011, 286(47):40725-40733.
80. Acharya A., Das I., Chandhok D., Saha T. Redox regulation in cancer: A double-edged sword with therapeutic potential. Oxidative medicine and cellular longevity 2010, 3(1):23-34.
81. Stefansson O.A., Villanueva A., Vidal A., Marti L., Esteller M. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics 2012, 7(11):1225-1229.